Our Bureau, Mumbai Wednesday, August 20, 2025, 17:15 Hrs [IST] ...

US FDA extends review timeline of Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II: Rockville, Maryland Wednesday, August 20, 2025, 18:00 Hrs [IST] ...

Medanta Hospital highlights growing burden of resistant hypertension despite medication in India: Our Bureau, Bengaluru Wednesday, August 20, 2025, 16:30 Hrs [IST] Medanta Hospita ...

CitiusTech acquires Health Data Movers to improve hospitals with Epic Systems implementation: Our Bureau, Bengaluru Wednesday, August 20, 2025, 16:40 Hrs [IST] CitiusTech, a leadi ...

Dr Lal PathLabs (DLPL) has adopted a deep learning-based AI module to detect lymph node metastasis, including micrometastasis, in cancer cases. The lab major said that has become the first laboratory ...

Nerveblox, the ultrasound AI for regional anaesthesia receives US FDA 510(k) clearance: Ankara Wednesday, August 20, 2025, 15:00 Hrs [IST] Nerveblox, an AI software solution by Sm ...

PCI Biotech discontinues development of PCL technology and evaluation of future operations: Oslo, Norway Wednesday, August 20, 2025, 14:00 Hrs [IST] PCI Biotech Holding ASA, a bio ...

RemeGen and Santen ink exclusive licensing agreement for ophthalmic innovative drug RC28-E in Greater China and Asian countries: Yantai, China Wednesday, August 20, 2025, 11:00 Hr ...

MedImpact offers low cost, unbranded ustekinumab-aekn biosimilar: San Diego, California Wednesday, August 20, 2025, 13:00 Hrs [IST] MedImpact Holdings Inc., the largest independen ...

Lupin launches bosentan tablets for oral suspension in US with 180-day exclusivity: Our Bureau, Mumbai Wednesday, August 20, 2025, 12:20 Hrs [IST] Global pharma major Lupin Limite ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

Boehringer Ingelheim & Palatin Technologies ink global research collaboration and licensing pact to develop innovative therapy for retinal diseases: Ingelheim, Germany Wednesday, ...